Ibogaine Microdosing Protocol: Complete Guide to Low-Dose Therapy
Evidence-based protocols for ibogaine microdosing: dosing schedules, benefits, risks, and how to use low-dose ibogaine safely
Ibogaine microdosing—the practice of taking sub-perceptual doses of ibogaine alkaloids on a regular schedule—has emerged as an alternative approach to traditional flood-dose ibogaine treatment. Unlike the single, high-dose"flood" experience (15-20 mg/kg) that produces profound altered consciousness, microdosing involves much smaller doses (typically 25-150 mg) taken periodically for sustained benefits without intense psychoactive effects.
⚠️ Important Disclaimer
Ibogaine microdosing lacks rigorous scientific evidence. No placebo-controlled trials exist. All information here is based on anecdotal reports, underground practitioner observations, and pharmacokinetic inference.
Ibogaine carries cardiac risks even at low doses. Proper medical screening is essential.
Understanding Ibogaine Microdosing
What Is Microdosing?
Microdosing involves taking approximately 1/10th to 1/20th of a psychoactive dose on a repeated schedule. The goal is to obtain therapeutic benefits without perceptual alterations, hallucinations, or disruption to daily functioning.
Flood Dose vs. Microdose:
- Flood dose: 15-20 mg/kg (1,050-1,400 mg for a 70 kg person)
- Microdose: 25-150 mg total dose (regardless of body weight)
Forms Used
Ibogaine Hydrochloride (HCl)
Pharmaceutical-grade, precise dosing
Total Alkaloid Extract (TA)
Contains ibogaine plus other iboga alkaloids (tabernanthine, ibogamine, etc.)
Raw Iboga Root Bark
Least standardized, variable alkaloid content (5-15%)
Proposed Mechanisms
- Noribogaine accumulation: Long half-life metabolite builds up, providing sustained anti-addiction effects
- Neuroplasticity enhancement: Low doses may promote GDNF production without cardiac risks of high doses
- Opioid receptor modulation: Partial mu-opioid agonism reduces cravings and withdrawal
- NMDA antagonism: Low-level blockade provides mild antidepressant effects
Intended Use Cases
- Addiction maintenance: After flood-dose treatment, microdosing helps maintain abstinence
- Mood stabilization: Anecdotal reports of antidepressant and anxiolytic effects
- Cognitive enhancement: Reports of improved focus and motivation (placebo not ruled out)
- Gradual healing: For those unable to undergo flood-dose treatment
Microdosing Protocols
Protocol 1: The Fadiman-Inspired Schedule (1 day on, 2 days off)
Adapted from psilocybin microdosing research:
- Day 1: Dose
- Day 2: No dose (observe effects)
- Day 3: No dose (baseline day)
- Day 4: Dose
- Repeat
Typical Doses:
- Ibogaine HCl: 25-50 mg
- Total alkaloid: 50-100 mg
- Root bark: 100-300 mg (highly variable)
Protocol 2: The Addiction Maintenance Protocol
For ongoing recovery support:
- Daily: 25-75 mg ibogaine HCl every morning
- OR every other day: 50-150 mg
Caution: Daily dosing increases cumulative cardiac risk. Periodic EKGs recommended but rarely obtained.
Protocol 3: The Intuitive Protocol (as-needed)
Take when cravings, anxiety, or depressive symptoms arise (no more than 2-3 times weekly)
Typical dose: 50-100 mg ibogaine HCl or 100-200 mg TA
Safety Considerations and Risks
⚠️ Cardiac Risk
Even low doses (25-75 mg) cause measurable QT prolongation in some individuals. With daily or frequent microdosing, the cardiac risk accumulates.
Baseline EKG before starting + follow-up EKG at 3 months is recommended. Most people self-dosing skip this critical safety step.
Drug Interactions
Dangerous combinations include:
- SSRIs/SNRIs (serotonin syndrome risk)
- MAOIs (potentially dangerous interaction)
- Stimulants (increased cardiac risk)
- Other QT-prolonging drugs
Legal Risk
Ibogaine is Schedule I in the United States (possession is illegal). Microdosing doesn't change legal status.Learn about legal status
Product Quality
Underground sources vary wildly in purity. Root bark alkaloid content can vary 3-fold between batches. Risk of contamination or incorrect dosing is real.
Evidence Base: What Research Exists?
As of 2026, no peer-reviewed, placebo-controlled trials have examined ibogaine microdosing.
Evidence consists entirely of anecdotal reports, online community surveys (with selection bias), and informal case series from underground practitioners.
What We Know From Pharmacokinetics
Noribogaine (ibogaine's long-lasting metabolite) builds up with repeated dosing. At steady state, noribogaine plasma concentrations from microdosing may approach levels seen days after a flood dose.
Implication: Microdosing may achieve therapeutically relevant noribogaine levels without acute high-dose exposure—but this is theoretical. No studies confirm clinical benefit.
What Ibogaine Microdosing Is NOT
❌ Not a replacement for flood-dose treatment: Microdosing does not produce the profound psychological reset of a flood dose
❌ Not FDA-approved or medically supervised: This is underground, unregulated practice
❌ Not risk-free: Cardiac risks exist even at low doses, especially with chronic use
❌ Not supported by rigorous evidence: Everything is anecdotal. Placebo effects are likely substantial
Why Most Clinics Focus on Flood-Dose Treatment
Leading ibogaine providers focus on flood-dose ibogaine treatment under comprehensive medical supervision rather than microdosing, for several reasons:
- Lack of evidence: No controlled human studies support microdosing efficacy
- Cardiac monitoring: Chronic microdosing requires ongoing surveillance most users don't obtain
- Flood dosing is more effective: For addiction and trauma, flood-dose treatment produces more robust outcomes
- Legal and ethical concerns: Providing substances for unsupervised chronic use raises safety issues
That said: We recognize that some patients may benefit from occasional low-dose"booster" treatments (200-300 mg every 3-6 months) administered in a clinical setting with cardiac monitoring. This is distinct from self-directed microdosing.
Considering Ibogaine Treatment?
For most people seeking ibogaine's benefits, a single flood-dose treatment under medical supervision is safer and more effective than months of unsupervised microdosing.